About Purdue Pharma

Purdue Pharma L.P. is a privately held pharmaceutical company founded by physicians more than 60 years ago. We are committed to improving patients’ lives in meaningful ways by providing effective therapies along with educational tools that support their proper use. Purdue Pharma is a member company of a global network of independent associated companies which are engaged in the research, development, production, and marketing of prescription and over-the-counter medicines and healthcare products. Distinguished by our pioneering research, products, and medical programs directed toward alleviating pain, Purdue Pharma is an industry leader in pain medication research and abuse-deterrent technology.

We are pursuing a promising pipeline of new medications through internal research & development and strategic industry partnerships. At Purdue Pharma, we embrace our mission to find, develop, and introduce innovative medicines that meet the evolving needs of healthcare professionals, patients, and caregivers.

Our History

  • 1892

    Dr. John Purdue Gray and George Frederick Bingham start The Purdue Frederick Company on Manhattan’s

    Lower East Side.

    1892

  • 1952

    Drs. Raymond and Mortimer Sackler purchase The Purdue Frederick Company and move the company to

    Christopher Street, New York City.

    1952

  • 1955

    Senokot® Laxatives are introduced in U.S.

    1955

  • 1958

    Cerumenex drops*, the first liquid agent for removing excess earwax, introduced.

    *Product no longer available.

    1958

  • 1959

    Arthropan (choline salicylate) liquid* for the treatment of arthritis introduced.

    *Product no longer available.

    1959

  • 1962

    Company relocates to Yonkers, NY.

    1962

  • 1966

    Betadine® broad-spectrum microbicides are acquired by Purdue.

    1966

  • 1969

    Betadine® Surgical Scrub* is used to decontaminate the Apollo lunar

    module after Neil Armstrong’s moonwalk.

    *Betadine products are not approved for use in the disinfection of inanimate objects.
    Photo credit: Records of the U.S. Information Agency; National Archives and Records

    Administration.

    1969

  • 1972

    Contin® controlled drug-release system is developed.

    1972

  • 1973

    Corporate headquarters relocates to South Norwalk, CT.

    1973

  • 1976

    Manufacturing relocates to Totowa, NJ.

    1976

  • 1977

    Trilisate (choline salicylate) tablets* for the treatment of arthritis introduced.

    *Product no longer available.

    1977

  • 1983

    Corporate headquarters relocates to Norwalk, CT. The company’s renovation of a former factory building

    won the Urban Land Institute Award for Excellence.

    1983

  • 1984

    Uniphyl tablets* – the world’s first oral theophylline designed for once-a-day use to control

    asthma – introduced.

    *Product no longer available.

    1984

  • 1987

    MS Contin® (morphine sulfate extended-release tablets) CII is launched. Click here for full

    Prescribing Information, including Boxed Warning.

    1987

  • 1991

    Purdue Pharma L.P. is formed.

    1991

  • 1993

    Purdue establishes Partners Against

    Pain® to help alleviate unnecessary suffering by advancing standards of

    chronic pain care through education.

    1993

  • 1996

    OxyContin® (oxycodone HCl) extended-release tablets CII is launched. Click here for full

    Prescribing Information, including Boxed Warning.

    1996

  • 2000

    Purdue relocates to One Stamford Forum, a distinctive tiered office tower in Stamford, CT.

    2000

  • 2000

    Purdue Pharmaceuticals L.P., a new manufacturing facility, is dedicated in Wilson, NC.

    2000

  • 2001

    Purdue occupies new headquarters building for discovery research and non-clinical development in

    Cranbury, NJ.

    2001

  • 2001

    Purdue develops Researched Abuse, Diversion and Addiction-Related Surveillance

    (RADARS®) System.

    2001

  • 2002

    Purdue Products L.P. is established and acquires Colace® Stool Softeners, Peri-Colace®

    Tablets, and Slow-

    Mag® Tablets.

    2002

  • 2003

    Stuart Baker named Counsel to the Board of Directors

    2003

  • 2003

    Purdue establishes RxPATROL®, a collaborative effort between industry and law

    enforcement designed to collect, collate, analyze, and disseminate pharmacy theft information.

    2003

  • 2004

    David Lundie joins Purdue Pharma as Head of Technical Operations

    2004

  • 2004

    Bert Weinstein appointed Chief Ethics & Compliance Officer

    2004

  • 2005

    Purdue licenses once-daily formulation of tramadol from Labopharm Inc. of Laval, Canada.

    2005

  • 2005

    Radio frequency ID tags and color-shifting ink integrated into OxyContin® packaging.

    2005

  • 2009

    Purdue licenses zolpidem tartrate sublingual tablets from Transcept Pharmaceuticals, Inc.

    2009

  • 2010

    Reformulation of OxyContin® (oxycodone HCl) extended-release tablets CII is launched.

    Click here for full

    Prescribing Information, including Boxed Warning.

    2010

  • 2010

    Rx Safety Matters website is launched.

    2010

  • 2011

    Butrans® (buprenorphine) Transdermal System CIII is launched. Click here for full

    Prescribing Information, including Boxed Warning.

    2011

  • 2012

    Philip C. Strassburger named General Counsel

    2012

  • 2012

    Intermezzo® (zolpidem tartrate) sublingual tablet CIV is launched. Click here for full

    Prescribing Information, including Boxed Warning.

    2012

  • 2013

    FDA approves new labeling in Section 9.2 of Full Prescribing Information for reformulated

    OxyContin (oxycodone HCl) extended-release tablets CII. Click here for full

    Prescribing Information, including Boxed Warning.

    2013

  • 2013

    FDA approves 15 mcg/hour dosage strength of Butrans. Click here for full

    Prescribing Information, including Boxed Warning.

    2013

  • 2014

    Saeed Motahari is named Chief Commercial Officer.

    2014

  • 2014

    Purdue Pharma L.P. Commercially Launches Recently Approved 7.5 mcg/hour Dosage Strength of

    Butrans® (Buprenorphine) Transdermal System CIII. Click here for full

    Prescribing Information, including Boxed Warning.

    2014

  • 2015

  • 2015

    Edward B. Mahony appointed Head of Due Diligence & Integration Management

    2015

  • 2015

    Zach Perlman appointed Chief of Staff to the Chief Executive Officer

    2015

  • 2015

    Alan W. Dunton, M.D. appointed Senior

    Vice President of Research & Development

    2015

  •  2015

  • 2015

    Eisai and Purdue Pharma Enter Worldwide Collaboration to

    Develop and Commercialize Lemborexant

    2015

  • 2015

  • 2015

    Purdue Pharma L.P. and AnaBios

    Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment

    2015

  • 2017

    Craig Landau, MD is named President & Chief Executive Officer.

    2017

  • Corporate
  • Products
  • Programs
  • Business
    Development